Protara Therapeutics will host a webinar on Lymphatic Malformations and TARA-002’s clinical program on May 19, 2026.
Quiver AI Summary
Protara Therapeutics, Inc. announced a virtual webinar scheduled for May 19, 2026, aimed at providing the investment community with insights into Lymphatic Malformations (LMs), the treatment landscape, and the TARA-002 clinical program. The event will feature expert perspectives on the disease burden, market opportunities, and regulatory considerations for TARA-002, which is an investigational cell therapy for both LMs and non-muscle invasive bladder cancer. TARA-002 has received several FDA designations for its innovative mechanism of action that targets immune responses against tumors. LMs are rare congenital malformations that frequently present in early childhood, leading to serious health complications. Protara is also developing additional therapies, including IV Choline Chloride for patients reliant on parenteral support. More details and access to the webinar will be available on Protara's website.
Potential Positives
- Protara Therapeutics is hosting a virtual webinar aimed at the investment community, which showcases the company's commitment to transparency and engagement with investors.
- The upcoming event will provide valuable insights into Lymphatic Malformations and the treatment landscape, highlighting Protara's expertise and focus on rare diseases.
- TARA-002 has received multiple prestigious FDA designations (Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy, and Fast Track), emphasizing its potential in addressing unmet medical needs.
- The detailed review of clinical data supporting TARA-002 during the webinar could enhance investor confidence and interest in Protara's clinical programs.
Potential Negatives
- The reliance on an investigational therapy (TARA-002) which has not yet received approval may raise concerns regarding regulatory and market viability.
- The press release emphasizes the serious manifestations of Lymphatic Malformations, potentially highlighting the severity of the condition and urgency for effective treatments, which could indicate a high level of risk for the ongoing clinical programs.
- The need for ongoing clinical trials and development stages presents inherent uncertainties in timelines and success rates, which may impact investor confidence.
FAQ
What is the focus of the upcoming Protara webinar?
The webinar will cover Lymphatic Malformations, the treatment landscape, and the TARA-002 clinical program.
How can I access the Protara webinar?
You can access the live event and accompanying slides via the Events and Presentations section of Protara's website.
What is TARA-002?
TARA-002 is an investigational cell therapy being developed for Lymphatic Malformations and non-muscle invasive bladder cancer.
What designations has TARA-002 received from the FDA?
TARA-002 has been granted Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy, and Fast Track designations by the FDA.
What are Lymphatic Malformations?
Lymphatic Malformations are rare congenital malformations causing lymphatic vessels to improperly connect or drain, often diagnosed in early childhood.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TARA Insider Trading Activity
$TARA insiders have traded $TARA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TARA stock by insiders over the last 6 months:
- JACQUELINE ZUMMO (Chief R&D Officer) sold 1,134 shares for an estimated $6,123
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TARA Hedge Fund Activity
We have seen 74 institutional investors add shares of $TARA stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 2,077,906 shares (+275.8%) to their portfolio in Q1 2026, for an estimated $10,825,890
- AIGH CAPITAL MANAGEMENT LLC added 1,622,733 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,454,438
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 1,259,427 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,561,614
- POINT72 ASSET MANAGEMENT, L.P. added 1,124,607 shares (+4001.2%) to their portfolio in Q1 2026, for an estimated $5,859,202
- PATIENT SQUARE CAPITAL LP added 1,030,846 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,370,707
- BLACKROCK, INC. added 986,100 shares (+40.9%) to their portfolio in Q1 2026, for an estimated $5,137,581
- CATALIO CAPITAL MANAGEMENT, LP removed 866,230 shares (-59.9%) from their portfolio in Q1 2026, for an estimated $4,513,058
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TARA Price Targets
Multiple analysts have issued price targets for $TARA recently. We have seen 4 analysts offer price targets for $TARA in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Brian Cheng from JP Morgan set a target price of $26.0 on 05/14/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $27.0 on 04/29/2026
- Kelsey Goodwin from Piper Sandler set a target price of $24.0 on 01/07/2026
Full Release
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and regulatory path for TARA-002 and a review of clinical data supporting the use of TARA-002 in LMs.
The live event and accompanying slides can be accessed visiting the Events and Presentations section of the Company’s website https://ir.protaratx.com . A replay of the webcast will be archived for a limited time following the event.
About TARA-002
TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy and Fast Track designations by the FDA. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes with a mechanism of action that includes the activation of innate and adaptive immune pathways. When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with the release of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IL-6, IL-10 and IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.
TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd.
About Lymphatic Malformations
Lymphatic Malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Protara’s focus is on macrocystic and mixed cystic LMs, for which there are no currently approved therapies. They are most frequently present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of three years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels and lymphatics; recurrent infection; and cosmetic and other functional disabilities. TARA-002 has been granted Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy and Fast Track designations by the FDA for the treatment of LMs.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com .
Company Contact:
Justine O'Malley
Protara Therapeutics
[email protected]
646-817-2836
